What age group can now receive Vertex’s Casgevy gene therapy?

The FDA has expanded Casgevy’s approval to include children as young as two years old with sickle cell disease or transfusion‑dependent beta thalassemia. Previously limited to patients 12 and older, the CRISPR‑based therapy’s broader label opens treatment to a much wider pediatric population and reshapes its clinical and commercial potential.